NKG2C/ KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma.

Olaya de DiosM Angeles Ramírez-GonzálezIrene Gómez-SoriaBerta Segura-CollarJuliana ManosalvaDiego MegíasCarlos E De AndreaLeticia Fernández-RubioAurelio Hernández-LaínJuan M Sepúlveda-SánchezMaria E Rodríguez-RuizÁngel Pérez-NúñezDerek A WainwrightRicardo Gargini Vicente A Torres

Published in: Journal for immunotherapy of cancer (2024)

expression in shaping the immune profile of GBM and suggests that it is a predictive biomarker for positive responses to immune checkpoint inhibitor treatment in patients with GBM. Future studies could further validate this finding in prospective trials.

Keyphrases

poor prognosis
single cell
binding protein
long non coding rna
mesenchymal stem cells
bone marrow
combination therapy
replacement therapy